Which is better for phlegm removal in COPD, ambroxol tablets or ambroxol dispersible tablets?

In the treatment of sputum clearance for chronic obstructive pulmonary disease (COPD), ambroxol tablets and ambroxol dispersible tablets have equivalent efficacy, with identical active ingredients and pharmacological actions. The only difference lies in their formulations, which leads to variations in absorption speed; neither formulation is absolutely superior to the other. If there is no improvement in sputum expulsion after medication, or if symptoms such as worsened cough or difficulty breathing occur, medical advice should be sought promptly.

Both medications primarily contain ambroxol, which promotes secretion from serous glands in the respiratory mucosa, reduces mucus gland secretion, decreases sputum viscosity, stimulates the release of pulmonary surfactants, and enhances ciliary movement in the bronchi. These effects collectively facilitate sputum expulsion and alleviate difficult expectoration in COPD patients.

Ambroxol dispersible tablets disintegrate more rapidly and dissolve quickly in water, resulting in faster absorption and onset of action, making them suitable for patients with swallowing difficulties or those requiring rapid relief. Ambroxol tablets are conventional tablets that disintegrate and absorb more gradually, providing stable and sustained therapeutic effects, ideal for long-term maintenance therapy in patients with normal swallowing function and stable conditions.

During treatment, medication should be taken strictly according to the prescribed dose under medical guidance. Self-adjustment of dosage should be avoided. Patients should drink plenty of water to help dilute and expel sputum, maintain appropriate indoor humidity, avoid smoking and exposure to irritants such as dust and fumes, and perform breathing exercises to assist sputum clearance and enhance overall treatment effectiveness.